Stereotactic radiosurgery for the treatment of brain metastasis from gastrointestinal primary cancers

Nitika Paudel, Irene Helenowski, Liam Kane, Sean Sachdev, Orin Bloch, Matthew Christopher Tate, James P Chandler, Timothy Joseph Kruser*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Purpose: We aimed to determine the efficacy of gamma knife stereotactic radiosurgery (SRS) to control brain metastases (BM) from GI primaries and report on the patient outcomes. Materials/methods: We retrospectively evaluated patients who had undergone SRS at our institution for the treatment BM from GI primaries from 2000 to 2016. Actuarial rates for overall survival (OS) and local control (LC) were calculated. Survival rates were computed via the Kaplan-Meier method from the day of SRS. Multivariate analysis (MVA) using proportional hazards regression was done to determine prognostic factors for OS and LC. Results: 53 patients with a total of 148 BM were treated with SRS. The median age at SRS was 60 years and the median treatment dose was 18 Gy. SRS was given as an adjuvant treatment to 30.4% of lesions. Twelve patients underwent second course of SRS for new/recurrent lesions at a median of 8 months from the first SRS (range 2-25.5). Twelve patients (22.6%) received salvage whole brain radiation. The median follow up time from the diagnosis of BM was 6 months. Local control rate at 6 months was 74.33% and 57.21% at 12 months. The OS at 1 year was 34% and 8% at 3 years. On MVA, higher GK dose was associated with better LC, and and >10 BM trended towards higher risk of local recurrence (LR). None of the tested factors proved to be significant for OS on MVA. No radiographic radionecrosis was observed on follow up MRI. Conclusions: SRS is a safe treatment modality for the management of CNS metastases from GI primary. Consideration for dose-escalated approaches may improve LC rates.

Original languageEnglish (US)
Pages (from-to)27-34
Number of pages8
JournalJournal of Radiosurgery and SBRT
Volume6
Issue number1
StatePublished - Jan 1 2019

Fingerprint

Gastrointestinal Neoplasms
Radiosurgery
Neoplasm Metastasis
Brain
Therapeutics
Multivariate Analysis
Survival
Survival Rate
Radiation
Recurrence

Keywords

  • Brain metastases
  • Gastrointestinal cancers
  • Radiotherapy
  • Stereotactic radiosurgery

ASJC Scopus subject areas

  • Surgery
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

@article{4c679683538c4226bc8f32f7f709303c,
title = "Stereotactic radiosurgery for the treatment of brain metastasis from gastrointestinal primary cancers",
abstract = "Purpose: We aimed to determine the efficacy of gamma knife stereotactic radiosurgery (SRS) to control brain metastases (BM) from GI primaries and report on the patient outcomes. Materials/methods: We retrospectively evaluated patients who had undergone SRS at our institution for the treatment BM from GI primaries from 2000 to 2016. Actuarial rates for overall survival (OS) and local control (LC) were calculated. Survival rates were computed via the Kaplan-Meier method from the day of SRS. Multivariate analysis (MVA) using proportional hazards regression was done to determine prognostic factors for OS and LC. Results: 53 patients with a total of 148 BM were treated with SRS. The median age at SRS was 60 years and the median treatment dose was 18 Gy. SRS was given as an adjuvant treatment to 30.4{\%} of lesions. Twelve patients underwent second course of SRS for new/recurrent lesions at a median of 8 months from the first SRS (range 2-25.5). Twelve patients (22.6{\%}) received salvage whole brain radiation. The median follow up time from the diagnosis of BM was 6 months. Local control rate at 6 months was 74.33{\%} and 57.21{\%} at 12 months. The OS at 1 year was 34{\%} and 8{\%} at 3 years. On MVA, higher GK dose was associated with better LC, and and >10 BM trended towards higher risk of local recurrence (LR). None of the tested factors proved to be significant for OS on MVA. No radiographic radionecrosis was observed on follow up MRI. Conclusions: SRS is a safe treatment modality for the management of CNS metastases from GI primary. Consideration for dose-escalated approaches may improve LC rates.",
keywords = "Brain metastases, Gastrointestinal cancers, Radiotherapy, Stereotactic radiosurgery",
author = "Nitika Paudel and Irene Helenowski and Liam Kane and Sean Sachdev and Orin Bloch and Tate, {Matthew Christopher} and Chandler, {James P} and Kruser, {Timothy Joseph}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "6",
pages = "27--34",
journal = "Journal of Radiosurgery and SBRT",
issn = "2156-4639",
publisher = "Old City Publishing",
number = "1",

}

Stereotactic radiosurgery for the treatment of brain metastasis from gastrointestinal primary cancers. / Paudel, Nitika; Helenowski, Irene; Kane, Liam; Sachdev, Sean; Bloch, Orin; Tate, Matthew Christopher; Chandler, James P; Kruser, Timothy Joseph.

In: Journal of Radiosurgery and SBRT, Vol. 6, No. 1, 01.01.2019, p. 27-34.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stereotactic radiosurgery for the treatment of brain metastasis from gastrointestinal primary cancers

AU - Paudel, Nitika

AU - Helenowski, Irene

AU - Kane, Liam

AU - Sachdev, Sean

AU - Bloch, Orin

AU - Tate, Matthew Christopher

AU - Chandler, James P

AU - Kruser, Timothy Joseph

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: We aimed to determine the efficacy of gamma knife stereotactic radiosurgery (SRS) to control brain metastases (BM) from GI primaries and report on the patient outcomes. Materials/methods: We retrospectively evaluated patients who had undergone SRS at our institution for the treatment BM from GI primaries from 2000 to 2016. Actuarial rates for overall survival (OS) and local control (LC) were calculated. Survival rates were computed via the Kaplan-Meier method from the day of SRS. Multivariate analysis (MVA) using proportional hazards regression was done to determine prognostic factors for OS and LC. Results: 53 patients with a total of 148 BM were treated with SRS. The median age at SRS was 60 years and the median treatment dose was 18 Gy. SRS was given as an adjuvant treatment to 30.4% of lesions. Twelve patients underwent second course of SRS for new/recurrent lesions at a median of 8 months from the first SRS (range 2-25.5). Twelve patients (22.6%) received salvage whole brain radiation. The median follow up time from the diagnosis of BM was 6 months. Local control rate at 6 months was 74.33% and 57.21% at 12 months. The OS at 1 year was 34% and 8% at 3 years. On MVA, higher GK dose was associated with better LC, and and >10 BM trended towards higher risk of local recurrence (LR). None of the tested factors proved to be significant for OS on MVA. No radiographic radionecrosis was observed on follow up MRI. Conclusions: SRS is a safe treatment modality for the management of CNS metastases from GI primary. Consideration for dose-escalated approaches may improve LC rates.

AB - Purpose: We aimed to determine the efficacy of gamma knife stereotactic radiosurgery (SRS) to control brain metastases (BM) from GI primaries and report on the patient outcomes. Materials/methods: We retrospectively evaluated patients who had undergone SRS at our institution for the treatment BM from GI primaries from 2000 to 2016. Actuarial rates for overall survival (OS) and local control (LC) were calculated. Survival rates were computed via the Kaplan-Meier method from the day of SRS. Multivariate analysis (MVA) using proportional hazards regression was done to determine prognostic factors for OS and LC. Results: 53 patients with a total of 148 BM were treated with SRS. The median age at SRS was 60 years and the median treatment dose was 18 Gy. SRS was given as an adjuvant treatment to 30.4% of lesions. Twelve patients underwent second course of SRS for new/recurrent lesions at a median of 8 months from the first SRS (range 2-25.5). Twelve patients (22.6%) received salvage whole brain radiation. The median follow up time from the diagnosis of BM was 6 months. Local control rate at 6 months was 74.33% and 57.21% at 12 months. The OS at 1 year was 34% and 8% at 3 years. On MVA, higher GK dose was associated with better LC, and and >10 BM trended towards higher risk of local recurrence (LR). None of the tested factors proved to be significant for OS on MVA. No radiographic radionecrosis was observed on follow up MRI. Conclusions: SRS is a safe treatment modality for the management of CNS metastases from GI primary. Consideration for dose-escalated approaches may improve LC rates.

KW - Brain metastases

KW - Gastrointestinal cancers

KW - Radiotherapy

KW - Stereotactic radiosurgery

UR - http://www.scopus.com/inward/record.url?scp=85062466507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062466507&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 27

EP - 34

JO - Journal of Radiosurgery and SBRT

JF - Journal of Radiosurgery and SBRT

SN - 2156-4639

IS - 1

ER -